Product Development

Data Graphics


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">The TREM2 pipeline: Date Byte</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1ef7l34r60">It&#x2019;s early days for the target, but the therapies directed at the innate immune receptor has begun to reflect its potential</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Danielle GOlovin, Staff Writer</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Alector Inc.

AbbVie Inc.

Denali Therapeutics Inc.

Takeda Pharmaceutical Co. Ltd.

Ionis Pharmaceuticals Inc.

Pionyr Immunotherapeutics Inc.

Abcam plc

Vigil Neuroscience Inc.

Amgen Inc.

Autobahn Therapeutics Inc.

Gilead Sciences Inc.

AL002

DNL919 (ATV:TREM2)

PY314

ABX-003

Triggering receptor expressed on myeloid cells 2 (TREM2)

The TREM2 pipeline: Date Byte

It’s early days for the target, but the therapies directed at the innate immune receptor have begun to reflect its potential.

It’s early days for the target, but the therapies directed at the innate immune receptor has begun to reflect its potential

Featured Analysis

Articles by Category

Current Editions

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>